scholarly journals Multinodular lung infiltrate in a patient with lymphoma: metastasis, tuberculosis or other?

2017 ◽  
Vol 2017 (3) ◽  
Author(s):  
Keisuke Anan ◽  
Kodai Kawamura ◽  
Norikazu Mitsui ◽  
Kazuya Ichikado
Keyword(s):  
2019 ◽  
Vol 05 (03) ◽  
Author(s):  
Nikhil Madan ◽  
Carolina Pinzon Escobar ◽  
Vipul Patel

Respirology ◽  
2008 ◽  
Vol 13 (3) ◽  
pp. 478-480 ◽  
Author(s):  
Sin-Man LAM ◽  
Arthur Chun-Wing LAU ◽  
Ming-Wai MA ◽  
Loretta Yin-Chun YAM

2003 ◽  
Vol 21 (6) ◽  
pp. 1078-1080 ◽  
Author(s):  
C. Raynaud ◽  
B. Crestani ◽  
M. Grossin ◽  
M. Piperaud ◽  
M-C. Dombret ◽  
...  

Thorax ◽  
2008 ◽  
Vol 63 (10) ◽  
pp. 876-876
Author(s):  
P-Y Lin ◽  
C-J Yu ◽  
M Yao ◽  
S-C Ku ◽  
L-N Lee ◽  
...  

2012 ◽  
Vol 97 (12) ◽  
pp. 1097-1101 ◽  
Author(s):  
L Peter Ormerod

The scientific basis of drug treatment for both active tuberculosis (TB) disease and TB infection, has been established, with treatment in children being largely extrapolated from adult active disease trials. It is essential that active TB disease is excluded before asymptomatic TB infection is diagnosed and treated. Nearly half of all children with active TB disease are found as asymptomatic tuberculin, or interferon gamma release assay (IGRA), positive contacts on screening by local TB services, usually of sputum TB microscopy positive adult relatives or other index cases, but with evidence of lung infiltrate or mediastinal lymphadenopathy on the child's chest x-ray. New drug regimens for both active disease and latent infection are in development, and also some novel drugs. However, none of these have yet been tested in children, and so again data will need to be extrapolated from adult results. In addition, there are issues regarding pharmacokinetics and dosing for current drugs, particularly isoniazid.


2018 ◽  
Vol 54 (2) ◽  
pp. 103-104
Author(s):  
José Antonio Delgado Torralbo ◽  
Luis Carlos García Gómez ◽  
Juan Manuel Sánchez Varilla

2020 ◽  
Vol 9 (12) ◽  
pp. 4129
Author(s):  
Rohit Khullar ◽  
Shrey Shah ◽  
Gagandeep Singh ◽  
Joseph Bae ◽  
Rishabh Gattu ◽  
...  

Patients receiving mechanical ventilation for coronavirus disease 2019 (COVID-19) related, moderate-to-severe acute respiratory distress syndrome (CARDS) have mortality rates between 76–98%. The objective of this retrospective cohort study was to identify differences in prone ventilation effects on oxygenation, pulmonary infiltrates (as observed on chest X-ray (CXR)), and systemic inflammation in CARDS patients by survivorship and to identify baseline characteristics associated with survival after prone ventilation. The study cohort included 23 patients with moderate-to-severe CARDS who received prone ventilation for ≥16 h/day and was segmented by living status: living (n = 6) and deceased (n = 17). Immediately after prone ventilation, PaO2/FiO2 improved by 108% (p < 0.03) for the living and 150% (p < 3 × 10−4) for the deceased. However, the 48 h change in lung infiltrate severity in gravity-dependent lung zones was significantly better for the living than for the deceased (p < 0.02). In CXRs of the lower lungs before prone ventilation, we observed 5 patients with confluent infiltrates bilaterally, 12 patients with ground-glass opacities (GGOs) bilaterally, and 6 patients with mixed infiltrate patterns; 80% of patients with confluent infiltrates were alive vs. 8% of patients with GGOs. In conclusion, our small study indicates that CXRs may offer clinical utility in selecting patients with moderate-to-severe CARDS who will benefit from prone ventilation. Additionally, our study suggests that lung infiltrate severity may be a better indicator of patient disposition after prone ventilation than PaO2/FiO2.


Sign in / Sign up

Export Citation Format

Share Document